



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: David M. GOLDENBERG *et al.*

Title: IMMUNOTHERAPY OF
AUTOIMMUNE DISORDERS
USING ANTIBODIES WHICH
TARGET B-CELLS

Appl. No.: 09/590,284

Filing Date: June 9, 2000

Examiner: J. Roark

Art Unit: 1644

#18
970
RECEIVED
FEB 11 2003
TECH CENTER 1600/2900
TC 1700 MAIL ROOM
RECEIVED
FEB -7 2003

AMENDMENT AND REQUEST FOR RECONSIDERATION UNDER 37 CFR §1.111

Commissioner for Patents
Washington, D.C. 20231

Sir:

In reply to the communication dated September 5, 2002, applicants request that the above-identified application be amended and reconsidered in light of the remarks that follow

In the claims

Please enter the following amended versions of claims 1 and 12 into the record. A marked-up version showing changes made is appended.

B1
1. (Amended) A method for treating an autoimmune disorder, comprising administering to a subject having an autoimmune disorder a therapeutic composition comprising a pharmaceutically acceptable carrier and at least one antibody to a B-cell antigen selected from the group consisting of CD22, CD20 and CD19.

B2
12. (Amended) The method of claim 1, wherein said B-cell antigen is CD20.